Pharmaceutical co-crystal compositions
First Claim
1. A pharmaceutical co-crystal composition, comprising:
- an API and a co-crystal former, wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and co-crystal former are hydrogen bonded to each other.
5 Assignments
0 Petitions
Accused Products
Abstract
A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp2 amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.
-
Citations
37 Claims
-
1. A pharmaceutical co-crystal composition, comprising:
- an API and a co-crystal former, wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and co-crystal former are hydrogen bonded to each other.
- View Dependent Claims (2, 9, 10, 37)
-
3. A pharmaceutical co-crystal composition, comprising:
- an API, a co-crystal former, and a third molecule;
wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and the third molecule are bonded to each other, and further wherein the co-crystal former and the third molecule are hydrogen bonded to each other. - View Dependent Claims (4)
- an API, a co-crystal former, and a third molecule;
-
5. A pharmaceutical co-crystal composition, comprising:
- a first and a second API, wherein each API is either a liquid or a solid at room temperature, and wherein the APIs are hydrogen bonded to a molecule.
- View Dependent Claims (6)
-
7. A pharmaceutical co-crystal composition, comprising:
- a first and a second co-crystal former, wherein each co-crystal former is a solid at room temperature, and wherein both co-crystal formers are hydrogen bonded to a molecule.
- View Dependent Claims (8)
-
11. A co-crystal comprising an API and a co-crystal former selected from:
-
(a) carbamazepine and saccharin;
(b) carbamazepine and nicotinamide;
(c) carbamazepine and trimesic acid;
(d) celecoxib and nicotinamide;
(e) olanzapine and nicotinamide;
(f) celecoxib and 18-crown-6;
(g) itraconazole and succinic acid;
(h) itraconazole and fumaric acid;
(i) itraconazole and tartaric acid;
(j) itraconazole and malic acid;
(k) itraconazoleHCl and tartaric acid;
(l) modafinil and malonic acid;
(m) modafinil and benzamide;
(n) modafinil and mandelic acid;
(o) modafinil and glycolic acid;
(p) modafinil and fumaric acid;
(q) modafinil and maleic acid;
(r) topiramate and 18-crown-6;
(s) 5-fluorouracil and urea;
(t) hydrochlorothiazide and nicotinic acid;
(u) hydrochlorothiazide and 18-crown-6;
(v) hydrochlorothiazide and piperazine;
(w) acetaminophen and 4,4′
-bipyridine;
(x) phenytoin and pyridone;
(y) aspirin and 4,4′
-bipyridine;
(z) ibuprofen and 4,4′
-bipyridine;
(aa) flurbiprofen and 4,4′
-bipyridine;
(bb) flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene;
(cc) carbamazepine and p-phthalaldehyde;
(dd) carbamazepine and 2,6-pyridinecarboxylic acid;
(ee) carbamazepine and 5-nitroisophthalic acid;
(ff) carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid;
or(gg) carbamazepine and benzoquinone.
-
-
12. A process for preparing a pharmaceutical co-crystal composition comprising an API and a co-crystal former, comprising:
-
(a) providing an API and a co-crystal former, wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature;
(b) grinding, heating, or contacting in solution the API with the co-crystal former under crystallization conditions, so as to form a solid phase, wherein the API and co-crystal former are hydrogen bonded to each other;
(c) isolating co-crystals formed thereby; and
(d) incorporating the co-crystals into a pharmaceutical composition. - View Dependent Claims (13, 20, 21)
-
-
14. A process for preparing a pharmaceutical co-crystal composition comprising an API, a co-crystal former, and a third molecule, comprising:
-
(a) providing an API and a co-crystal former, wherein the API is a liquid or a solid at room temperature and the co-crystal former is a solid at room temperature;
(b) grinding, heating, or contacting in solution the API with the co-crystal former under crystallization conditions, so as to form a solid phase, wherein the API and the third molecule are bonded to each other, and further wherein the co-crystal former and the third molecule are hydrogen bonded to each other;
(c) isolating co-crystals formed thereby; and
(d) incorporating the co-crystals into a pharmaceutical composition. - View Dependent Claims (15)
-
-
16. A process for preparing a pharmaceutical co-crystal composition comprising a first and a second API, comprising:
-
(a) providing a first and a second API, wherein each API is either a liquid or a solid at room temperature;
(b) grinding, heating, or contacting in solution the APIs under crystallization conditions, so as to form a solid phase, wherein the APIs are hydrogen bonded to a molecule;
(c) isolating co-crystals formed thereby; and
(d) incorporating the co-crystals into a pharmaceutical composition. - View Dependent Claims (17)
-
-
18. A process for preparing a pharmaceutical co-crystal composition comprising a first and a second co-crystal former, comprising:
-
(a) providing a first and a second co-crystal former, wherein each co-crystal former is a solid at room temperature;
(b) grinding, heating, or contacting in solution the co-crystal formers under crystallization conditions, so as to form a solid phase, wherein both co-crystal formers are hydrogen bonded to a molecule;
(c) isolating co-crystals formed thereby; and
(d) incorporating the co-crystals into a pharmaceutical composition. - View Dependent Claims (19)
-
-
22. A process of preparing a co-crystal comprising an API and a co-crystal former, comprising:
-
(a) providing an API and a co-crystal former;
(b) grinding, heating, or contacting in solution the API with the co-crystal former under crystallization conditions, so as to form a solid phase; and
(c) isolating co-crystals formed thereby;
wherein the API and the co-crystal former are selected from carbamazepine and saccharin, carbamazepine and nicotinamide, carbamazepine and trimesic acid, celecoxib and nicotinamide, olanzapine and nicotinamide, celecoxib and 18-crown-6, itraconazole and succinic acid, itraconazole and fumaric acid, itraconazole and tartaric acid, itraconazole and malic acid, itraconazoleHCl and tartaric acid, modafinil and malonic acid, modafinil and benzamide, modafinil and mandelic acid, modafinil and glycolic acid, modafinil and fumaric acid, modafinil and maleic acid, topiramate and 18-crown-6,5-fluorouracil and urea, hydrochlorothiazide and nicotinic acid, hydrochlorothiazide and 18-crown-6, hydrochlorothiazide and piperazine, acetaminophen and 4,4′
-bipyridine, phenytoin and pyridone, aspirin and 4,4′
-bipyridine, ibuprofen and 4,4′
-bipyridine, flurbiprofen and 4,4′
-bipyridine, flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene, carbamazepine and p-phthalaldehyde, carbamazepine and 2,6-pyridinecarboxylic acid, carbamazepine and 5-nitroisophthalic acid, carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid, or carbamazepine and benzoquinone.
-
-
23. A process for modulating the solubility of an API for use in a pharmaceutical composition, which process comprises:
-
(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
(b) isolating the co-crystal, wherein the co-crystal has a modulated solubility as compared to the API; and
(c) incorporating the co-crystal having modulated solubility into a pharmaceutical composition. - View Dependent Claims (24)
-
-
25. A process for modulating the dose response of an API for use in a pharmaceutical composition, which process comprises:
-
(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
(b) isolating the co-crystal, wherein the co-crystal has a modulated dose response as compared to the API; and
(c) incorporating the co-crystal having modulated dose response into a pharmaceutical composition. - View Dependent Claims (26)
-
-
27. A process for modulating the dissolution of an API for use in a pharmaceutical composition, which process comprises:
-
(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
(b) isolating the co-crystal, wherein the co-crystal has a modulated dissolution as compared to the API; and
(c) incorporating the co-crystal having modulated dissolution into a pharmaceutical composition. - View Dependent Claims (28)
-
-
29. A process for modulating the bioavailability of an API for use in a pharmaceutical composition, which process comprises:
-
(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
(b) isolating the co-crystal, wherein the co-crystal has a modulated bioavailability as compared to the API; and
(c) incorporating the co-crystal having modulated bioavailability into a pharmaceutical composition. - View Dependent Claims (30)
-
-
31. A process for increasing the stability of an API for use in a pharmaceutical composition, which process comprises:
-
(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
(b) isolating the co-crystal, wherein the co-crystal has increased stability as compared to the API; and
(c) incorporating the co-crystal having increased stability into a pharmaceutical composition.
-
-
32. A process for the incorporation of a difficult to salt or unsaltable API for use in a pharmaceutical composition, which process comprises:
-
(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
(b) isolating the co-crystal;
(c) incorporating the co-crystal having a difficult to salt or unsaltable API into a pharmaceutical composition.
-
-
33. A process for decreasing the hygroscopicity of an API for use in a pharmaceutical composition, which process comprises:
-
(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
(b) isolating the co-crystal, wherein the co-crystal has decreased hygroscopicity as compared to the API; and
(c) incorporating the co-crystal having decreased hygroscopicity into a pharmaceutical composition.
-
-
34. A process for crystallizing an amorphous API for use in a pharmaceutical composition, which process comprises:
-
(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
(b) isolating the co-crystal;
(c) incorporating the co-crystal into a pharmaceutical composition.
-
-
35. A process for decreasing the form diversity of an API for use in a pharmaceutical composition, which process includes:
-
(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
(b) isolating the co-crystal, wherein the co-crystal has decreased form diversity as compared to the API; and
(c) incorporating the co-crystal having decreased form diversity into a pharmaceutical composition.
-
-
36. A process for modulating the morphology of an API for use in a pharmaceutical composition, which process includes:
-
(a) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
(b) isolating the co-crystal, wherein the co-crystal has a different morphology as compared to the API; and
(c) incorporating the co-crystal having modulated morphology into a pharmaceutical composition.
-
Specification